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S U L L I V A N ,  S., H. A K I L ,  D. B L A C K E R  A N D  J. D. BARCHAS.  Enkephalinase: Selective inhibitors and partial 
characterization. PEPTIDES 1(1) 31-35, 1980.--There are at least two types of enzymes in brain, endopeptidases and 
aminopeptidases, which metabolize enkephalins. Evidence is presented to suggest that enkephalinase, an endopeptidase 
cleaving at the Gly-Phe bond, is specific for the endogenous enkephalinergic system. Selective inhibitors are described for 
each enzyme. These are parachloromercuriphenylsulfonic acid and puromycin in the case of aminopeptidases and various 
enkephalin fragments in the case of enkephalinase. Some characteristics of the two types of enzymes are described. 
Enkephalinase has many properties in common with the well-characterized brain angiotensin-converting enzyme. These 
two enzymes, however, behaved differently when tested for chloride dependance, for activity in several buffers and for 
susceptibility to specific inhibitors. 
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Enkephalinase and angiotensin converting enzyme Aminopeptidase metabolism of enkephalin 
SINCE the isolation from brain of the endogenous opiate- 
like peptides methionine- and leucine-enkephalin (ME and 
LE) [14], interest has been focused upon finding their physi- 
ological roles. These peptides apparently act as neuro- 
transmitters in brain: they are released in a CA÷+-dependent 
fashion by depolarization of striatal slices, are present in 
synaptosomes [13,15] and are localized in cell bodies and 
along beaded axons of interneurones [6, 22, 29]. With eluci- 
dation of modes of synthesis and inactivation at the synapse, 
additional requirements for the establishment of these sub- 
stances as neurotransmitters will be fulfilled. Synthetic 
mechanisms for these peptides remain unclear. There appear 
to be at least two modes of inactivation in brain, one via 
cleavage of  the N-terminal Tyr-Gly bond by (an) amino pep- 
tidase(s) [4, 12, 18, 19, 20] and a second via cleavage of the 
Gly-Phe bond [16, 24, 25] by (an) endopeptidase(s). In both 
cases enzymatic activity is probably comprised of a number 
of  peptidases. Amino peptidases are more soluble enzymes 
with brain distributions which do not follow that of 
enkephalin or the opiate receptor [20, 24, 25]. On the other 
hand, there is an endopeptidase which is membrane bound 
with a distribution in brain which parallels the opiate recep- 
tor [16, 17, 24, 25], suggesting that it is specific for the 
endogenous enkephalinergic system. The endopeptidase has 
been termed enkephalinase by some authors. Graves et al. 
[10] have recently demonstrated in vivo generation of Tyr- 
Gly-Gly (TGG) upon administration of '~H-enkephalin in 
brain, lending further credence to the idea that this endo- 
peptidase is physiolbgically significant. 
A purified peptidyldipeptidase identical to the angioten- 
sion converting enzyme (ACE) has been described as being 
capable of cleaving enkephalin at the Gly-Phe bond [8]. ACE 
has also been demonstrated to be present in brain [2, 21, 30]. 
This information engendered speculation on the part of Be- 
nuck and Marks [3], Swerts et al. [26], and Snyder [23] that 
brain enkephalinase activity may be attributable to ACE. 
In this paper we describe some work with inhibitors of the 
endopeptidase (enkephalinase) and amino peptidases, aimed 
at a preliminary characterization of these enzymes. The 
pharmacological use of selective inhibitors may later help to 
elucidate the roles of each mode of deactivation. In addition, 
enkephalinase inhibitors could be of potential therapeutic 
value. We also have been interested in the question as to 
whether enkephalinase is identical to ACE and have used 
inhibitors and other studies to address the issue of  identity 
between these two enzymes. We present here evidence that 




and (D-Ala2,-Leu 5) enkephalin were obtained from Bio- 
search. Angiotensin converting enzyme inhibitor was ob- 
tained from Beckman. Parachloromercuriphenyl sulfonic 
acid was obtained from Sigma. All other peptides and amino 
acids were from ICN. 
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Enzyme Assays 
The membrane preparation has been described in detail 
[25]. Briefly, bovine or rat caudate is homogenized in 100 
volumes of 0.1 M MES ph 6.5. After centrifugation at 30,000 
G for 20 min the pellet is resuspended in MES, centrifuged 
again, resuspended, and allowed to stand at room tempera- 
ture for one hour. The preparation is then centrifuged and 
the pellet is resuspended in 100 volumes of MES 0.1 M pH 
6.5. 
Fifty microliters of this preparation are incubated at 25°C 
for 2-10 min in the presence of 100 nM :~H-Leu-enkephalin 
(New England Nuclear) 25 Ci/mmole and, where applicable, 
10/zl of buffer or the inhibitor to be tested. Controls in which 
the membrane preparation has been boiled for one minute 
are run with each experiment. The reaction is terminated by 
spotting 10 tzl of the reaction mixture onto a thin-layer 
chromatography (TLC) plate of silica gel (0.5 mm thick). 
This procedure has previously been determined to give the 
same results as termination of reaction by boiling. Chro- 
matography is carried out in the system n-butanol:ethyl ace- 
tate:acetic acid:water (1:2:1:1). Markers of Leu-enkephalin, 
tyrosine (T), and TGG are run with all samples and the rele- 
vant areas are scraped into scintillation vials and counted. Rf 
values in this TLC system are TGG 0.25, T 0.38, and LE 
0.59. 
RESULTS 
inhibitors and Characterization 
Table 1 summarizes the effects of various classes of in- 
hibitors on both the TGG- and T-generation. In both cases 
enzymes appear to contain metal cofactors as evidenced by 
the strong inhibition produced by 1,10-phenanthroline and 
partial inhibition by EDTA. The minimal effect of EGTA 
indicates that both enzymes lack calcium dependence. 
Dialysis against 2000 volumes of buffer does not appreciably 
affect enzymatic activity, suggesting that metal cofactors are 
very strongly bound. Preliminary evidence from metal re- 
placement studies suggests Co ++ is the metal cofactor for 
enkephalinase. In these studies enzyme activity was tested 
in the presence of either 1 mM 1,10-phenanthroline, or 
phenanthroline plus various metals at a concentration of 4 
mM. Co ++ was the only metal with ability to restore activity 
to control levels. 
The sulfhydryl modifying agent, parachloromercur- 
iphenyl sulfonic acid (PCMP) was found to be a selective 
inhibitor for aminopeptidase activity, whereas the sulfhydryl 
reducing agent glutathione was slightly more potent as an 
inhibitor of enkephalinase. Sulfhydryl groups, then, are im- 
portant for the activity of both enzyme types. In the case of 
enkephalinase this appears to be via reduction of sulfhydryl 
bridges whereas for aminopeptidase activity inhibition oc- 
curs via reaction with - S H  groups. 
Degradation resistant analogues of Leu-enkephalin 
showed various inhibitory potencies. The two analogues al- 
tered at only one terminal elicited strong inhibition of both 
enzymes with the C-terminal modification having a greater 
effect on tyrosine generation and the N-terminal modifica- 
tion having a greater effect on TGG. D-Ala 2- 
Leu-enkephalinamide, with modification of both terminals, 
was far less potent, suggesting that at least one terminal must 
be unaltered to permit binding at active sites. This is in 
agreement with Grynbaum et al. [11] who have demon- 
strated a prolonged half-life for the doubly substituted 
analogue of Met-enkephalin. 
TABLE 1 
INHIBITORS 
Inhibitor at 1 mM Percent control _+ SEM 
(no. of trials) TGG T 
EGTA (4) 84.9 ± 8.4 100.5 _+ 13.4 
EDTA (5) 28.4 ± 5.9 37.9 _+ 8.8 
1,10 phenanthroline (9) 5.2 _+ 1.3 26.6 _+ 6.6 
Parachloromercuriphenyl 
sulfonic acid (10) 110.2 _+ 7.8 28.2 _+ 6.4 
Glutathione (4) 50.1 -- 3.2 71.1 _+ 5.2 
D-ala2-1eu-enkephalinamide (6) 49.2 _+ 4.8 38.9 _+ 4.4 
D-ala-21eu-enkephalin (6) 16.0 ± 3.3 28.0 ± 5.6 
Leu-enkephalinamide (3) 21.9 _+ 4.3 6.2 _+ 1.6 
Tyr-Gly (5) 15.2 -- 0.6 92.1 ± 7.6 
Tyr-Gly-Gly (5) 33.1 ± 1.4 94.5 ± 7.5 
Tyr-Gly-Gly-Phe (4) 24.8 _+ 1.0 25.5 ± 1.7 
Phe-Leu (5) 26.0 -- 2.1 47.3 ± 2.2 
Gly-Gly (4) 107.0 _+ 8.2 118.5 ± 8.0 
Gly-Gly-Phe (8), 10 min preinc. 88.2 + 2.3 75.4 _+ 5.3 
Gly-Gly-Phe (4), 2 min preinc. 70.4 _+ 1.5 62.4 _+ 2.3 
Gly-Phe (4) 40.8 _+ 4.4 85.6 ± 3.5 
GIy-GIy-DL-Phe (9) 29.8 ± 3.2 85.7 ± 6.4 
GIy-DL-Phe (5) 39.0 _+ 1.9 112.3 ± 12.1 
L-Phe (4) 108.2 ± 9.1 96.4 ± 2.5 
D-Phe (8) 92.0 ± 2.5 97.2 ± 6.3 
Tyr-Tyr, Leu-Leu, Leu-Gly (6) 10.8 ± 1.9 25.1 ± 4.5 
Puromycin (4) 107.0 ± 7.7 21.8 ± 1.9 
Bacitracin (5) 12.1 ± 1.5 14.3 _+ 3.2 
Inhibition of enkephalinase and aminopeptidase from rat striatum. 
Assays were performed as described in METHOD. All inhibitors 
were pre-incubated with the enzyme preparation for 10 min unless 
otherwise indicated. Control values were 0.9! ± 0.12 and 
1.48 ± 0.30 pmoles/mg tissue/hr for TGG and T generation respec- 
tively. 
Of the various enkephalin fragments tested, Tyr-Gly 
(TG), Tyr-Gly-Gly (TGG), and Gly-Phe (GP) are selective 
for enkephalinase. In the case of TG and TGG, the inhibition 
may be via end product feedback, whereas GP may be acting 
through a competitive mechanism. It is of interest to note 
GIy-Gly-D,L-Phe (GGd/P) and Gly-D,L-Phe (GDLP) are 
also highly selective for enkephalinase. It was puzzling that 
Giy-Gly-Phe (GGP) was found to be a poor inhibitor. How- 
ever, Gly-Gly-Phe's increased potency when the pre- 
incubation time was reduced from 10 to 2 min suggests that 
!ow potency is due to metabolism during preincubation. 
Marks et al. [18] have shown that in brain homogenates 
enkephalin is ultimately degraded to Gly-Gly which is rela- 
tively stable to peptidases. In our preparation, this dipeptide 
has relatively little inhibitory activity on either of the 
enzymes. 
In light of the report by Ehrenpreis [5] that systemically 
administered D-phenylalanine has analgesic properties, it 
was of interest to test whether decreased enkephalin break- 
down could be the mechanism of this analgesia. In our in 
vitro system neither D-phenylalanine nor its L-isomer was 
able to inhibit either enzyme. 
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Henderson et al. [13] have reported that the combination 
of dipeptides Tyr-Tyr, Leu-Leu, Leu-Gly, will protect 
methionine enkephalin from breakdown in their striatal slice 
preparations. This combination in our system inhibits both 
enzymes, with a greater potency for enkephalinase. 
Vogel and Altstein [28] have reported that puromycin 10 
/zM is able to inhibit enkephalin degradation in whole brain 
homogenates by 97% via inhibition of tyrosine generation. 
Our results confirm this finding but demonstrate no inhibi- 
tion of enkephalinase. 
Bacitracin is commonly used as a protective agent for 
enkephalins in binding assays. We found this antibiotic in- 
hibits both TGG and T generation. 
Comparison with Angiotensin Converting Enzyme 
There are a number of similarities between angiotensin 
converting enzyme and enkephalinase. Both are mem- 
brane-bound enzymes, present in brain, and capable of 
cleaving enkephalin at the Gly-Phe bond. Both are metal- 
loenzymes which are strongly inhibited by 1,10-phenan- 
throline. ACE in brain exhibits its highest activity in stri- 
atum as does enkephalinase. Hence there was reason to 
investigate the possibility that these may be identical 
enzymes. Our inhibitor studies had suggested a further simi- 
larity in that glutathione, known to inhibit ACE [7], also 
produced some inhibition of enkephalinase. However some 
differences between the two enzymes had also become ap- 
parent. Regional distribution in areas such as cerebellum, 
hypothalamus, and brainstem are apparently different for the 
two enzymes [3, 16, 17, 21, 24, 25, 30] and EDTA 1 mM 
produces complete inhibition of ACE but only 70% inhibition 
of enkephalinase. 
We tested enkephalinase for two well-documented prop- 
erties of ACE, namely its chloride dependence and its pow- 
erful inhibition by a nonapeptide derived from snake venom. 
Table 2 illustrates the effect of this inhibitor, pGlu-Trp-Pro- 
Arg-Pro-Gln-Ile-Pro-ProOh, on enkephalinase. At a concen- 
tration of 200/xm there is a 47% inhibition which is in marked 
TABLE 2 
ACE inhibitor/xM Percent control/SEM 
TGG T 
0.1 (5) 97.7 _+ 3.4 85.6 _+ 4.9 
1.0 (5) 90.2 _+ 2.6 91.3 _+ 4.3 
10.0 (5) 90.9 _+ 3.7 85.0 _+ 6.1 
100.0 (5) 58.6 _+ 5.0 91.1 +_ 6.0 
200.0 (3) 51.1 _+ 7.0 82.3 _+ 3.0 
Inhibition curve for the ACE inhibitor p-Glu-Trp-Pro-Arg-Pro- 
GIn-Iie-Pro ProOh (Beckman). Enzyme activity was assayed as 
described in METHOD. Numbers in parentheses represent the 
number of estimations. Control values were TGG 0.85 _+ 0.15 and T 
1.78 _+ 0.47 pmoles/mg tissue/hr. Tissue source was rat striatum. 
contrast to ACE from rat brain for which this nonapeptide 
has an IC.~0 of 0.1 tzM or less [30]. 
We tested the issue of chloride dependence in two ways. 
First we studied the activity of enkephalinase in different 
buffer systems, with and without addition of chloride. We 
then dialyzed the enzyme and again looked at activity in the 
presence and absence of chloride. Data presented in Table 3 
demonstrate that, of the buffers tested, enkephalinase was 
active only in tris-HC1 and MES. No activity could be shown 
in sodium or potassium phosphate or in tris-maleate buffers. 
Addition of chloride had no effect in any buffer system. Ex- 
tensive dialysis of the enzyme did not significantly alter ac- 
tivity and addition of chloride to the dialyzed enzyme had no 
effect. There are two points to note here: ACE of rat brain is 
reported to be active in both sodium and potassium phos- 
phate buffers [21,30] whereas enkephalinase is not. More- 
over, rat brain ACE becomes inactive upon dialysis against 
chloride-free buffer, activity being restored with the addition 
of chloride, while enkephalinase is unaffected by chloride. 
TABLE 3 
BUFFER AND CHLORIDE DEPENDENCE 
Condition pmoles/mg tissue/hr Condition pmoles/mg tissue/hr 
_+ SEM 
MES (11) 0.91 -+ 0 . 1 2  Sodium phosphate No activity 
+ chloride No activity 
MES + chloride (5) 0.59 _+ 0.11 
Potassium phosphate No activity 
Tris HCI (6) 0.85 +_ 0.15 + Chloride No activity 
Dialysed prepa- 0.77 _+ 0.03 Tris maleate No activity 
ration (15) + chloride No activity 
Dialysed + 0.81 _+ 0.004 
chloride (2) 
Enkephalinase activity in different buffer systems in the presence and absence of 100 mM 
sodium chloride. All buffers were 0.1 M pH 6.5. Dialysis was performed for 18 hr against 5000 
volumes of MES buffer. Enzyme activity was measured as described in METHOD. Numbers in 
parentheses indicate the number of trials. 
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DISCUSSION 
In this paper we have addressed several issues pertinent 
to enkephalin degradation in brain. Our inhibitor studies 
have allowed preliminary characterization of enkephalinase 
and tyrosine-producing aminopeptidases in brain. Enke- 
phalinase appears to be membrane-bound while the amino- 
peptidases are more soluble. Both types of enzyme are 
metalloenzymes which are inhibited by modification of sulf- 
hydryl groups. T-generation is selectively inhibited by 
PCMS and puromycin while enkephalinase is inhibited by 
the enkephalin fragments TG, TGG, GP, GDLP and 
GGDLP. These selective inhibitors could prove to be useful 
in studies designed to test the physiological significance of 
each type of enzymatic cleavage. 
Both enzymes are strongly inhibited by Leu-enkephalin 
analogues. These analogues have been shown to produce 
powerful opiate-like effects when administered in vivo, ef- 
fects which have been attributed to their activation of opiate 
receptors. Since they are powerful inhibitors of enkephalin 
breakdown, it is also possible that they could increase 
endogenous enkephalin levels within the synapse and this 
may contribute to their in vivo activities. On the other hand, 
D-phenylalanine, which has been reported to produce 
analgesia apparently does not act by inhibiting enkephalin 
breakdown. 
With regard to the question of identity between ACE and 
enkephalinase, we have produced cogent evidence that these 
are different enzymes. Two characteristic properties of 
ACE, inhibition by a snake venom nonapeptide and chloride 
dependence, were tested in relation to enkephalinase. In 
both cases enkephalinase behaved very differently from 
ACE. In addition, ACE is active in sodium and potassium 
phosphate buffers whereas enkephalinase is not. Thus de- 
spite some similarities between ACE and enkephalinase it 
appears that these are different enzymes in brain. There is 
some controversy in the literature regarding this finding. Be- 
nuck and Marks [3] feel that the two enzymes are identical. 
However, recent studies by Swerts et al. [27], Gorenstein 
and Synder [9], and Arregui [1] support our contention. Each 
of these investigators have demonstrated differentiation be- 
tween enkephalinase and converting enzyme. 
The distribution of enkephalinase, then, parallels that of 
enkephalin and the opiate receptor [17,25]. We have shown 
here that enkephalinase is sensitive to inhibition by 
enkephalin fragments which could represent a feedback in- 
hibition. Enkephalinase can be distinguished by various 
means from amino-peptidases and converting enzyme in the 
systems we have studied. These data are consistent with 
enkephalinase I~eing the enzyme in brain which is specific for 
the endogenous enkephalinergic system. 
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